All In Biotech

Drug Trial Radar · NCT03528681

A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia.

A Phase 3 Multicenter, Prospective, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of ZS (Sodium Zirconium Cyclosilicate), in Patients With Hyperkalemia-HARMONIZE Asia

Last checked: Nov 20, 2026Latest source record: May 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 270 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

270

Actual

Start

May 6, 2021

Primary completion

Sep 15, 2022

Study completion Sep 15, 2022

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
May 18, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy of two different doses (5 and 10 g) of ZS orally administered once daily (qd) vs placebo in maintaining normokalemia in initially hyperkalemic patients having achieved normokalemia following 24 or 48 hours of initial ZS therapy (10g TID).

Conditions

  • Hyperkalemia

Interventions

  • Sodium Zirconium Cyclosilicate 5gDrug

    Suspension administered Sodium Zirconium Cyclosilicate 5g orally once daily for 28 days after the open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day for at most 2 days.

  • Sodium Zirconium Cyclosilicate 10gDrug

    Suspension administered Sodium Zirconium Cyclosilicate 10g orally once daily for 28 days after the open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day for at most 2 days.

  • PlaceboDrug

    Suspension administered orally placebo once daily for 28 days after the open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day for at most 2 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Least Square Mean S-K Level on Days 8-29Time frame: Days 8 to 29 (Randomized treatment study phase) used for model-based least squares mean computation

Locations

66 sites in 2 countries. Site status is shown where the registry gives one.

  • Research Site

    Baotou, China

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Bengbu, China

  • Research Site

    Changchun, China

  • Research Site

    Changsha, China

  • Research Site

    Changsha, China

  • Research Site

    Chengdu, China

  • Research Site

    Chengdu, China

  • Research Site

    Dalian, China

  • Research Site

    Dongguan, China

  • Research Site

    Fuzhou, China

  • Research Site

    Fuzhou, China

  • Research Site

    Guangzhou, China

  • Research Site

    Guangzhou, China

  • Research Site

    Guiyang, China

  • Research Site

    Haikou, China

  • Research Site

    Hangzhou, China

  • Research Site

    Hangzhou, China

  • Research Site

    Hefei, China

  • Research Site

    Hefei, China

  • Research Site

    Jilin City, China

  • Research Site

    Jinan, China

  • Research Site

    Jingzhou, China

  • Research Site

    Kunming, China

  • Research Site

    Kunming, China

  • Research Site

    Lanzhou, China

  • Research Site

    Nanchang, China

  • Research Site

    Ningbo, China

  • Research Site

    Qingdao, China

  • Research Site

    Shanghai, China

  • Research Site

    Shanghai, China

  • Research Site

    Shanghai, China

  • Research Site

    Suzhou, China

  • Research Site

    Taiyuan, China

  • Research Site

    Taiyuan, China

  • Research Site

    Tianjin, China

  • Research Site

    Tianjin, China

Showing 40 of 66 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.